• Price

Supplier Type

• Trader
• Manufacturer
• Reagent
• contract manufacturer
• custom synthesis

Supplier Region

• Hyderabad(7)
• Gujarat(14)
• Maharashtra(18)
• Ahmedabad(4)
• Mumbai(19)
• Nagpur(1)
• Haryana(2)
• New Delhi(3)
• Uttar Pradesh(4)
• Delhi(2)
• Tamil Nadu(1)
• Karnataka(2)
• Beijing(1)
• Vadodara(2)
• Pune(1)
• Andhra Pradesh(2)

Purity

• Z-VAD-FMK, CAS 187389-52-2, is a cell-permeable, irreversible, pan-caspase inhibitor.
• VETRANAL?, analytical standard
• United States Pharmacopeia (USP) Reference Standard
• The AhR Antagonist, also referenced under CAS 301326-22-7, controls the biological activity of AhR.
• synthetic, ≥90% (HPLC)
• solid, ≥98% (HPLC)
• solid
• reference standard
• puriss. p.a., absolute, ≥99.5% (GC)
• powder
• Potent, reversible, and cell-permeable proteasome inhibitor (Ki = 4 nM).
• Pharmaceutical Secondary Standards
• pharmaceutical secondary standard, certified reference material
• Pharmaceutical Secondary Standard
• NLT 95%
• Min. 99%
• LRRK2-IN-1 primarily used in Inhibition.
• InSolution,≥95%
• InSolution, ≥99%, 50 mM in DMSO, RI Kinase Inhibitor II, RepSox
• InSolution, ≥98%, 5 mg/ml, reversible inhibitor of MAP Kinase Kinase (MEK)
• InSolution, ≥98%, 25 mM in DMSO
• InSolution, ≥98%, 10 mM, reversible proteasome inhibitor
• InSolution, ≥98%, 10 mM, reversible and specific inhibitor of PI 3-kinase
• InSolution, ≥98%, 1 mg/ml, reversible inhibitor of p38 MAP kinase
• InSolution, ≥97%, 25 mM in DMSO
• InSolution, ≥95%, protein kinase C (PKC) inhibitor
• InSolution, ≥95%, Inhibitor of protein kinase C
• InSolution, ≥95%, inhibitor of cyclin-dependent kinases (CDKs)
• InSolution, ≥95%
• IC?? = 800 nM).
• Hesperadin primarily used in Inhibition.
• HCl 98%
• Greater than 99%
• European Pharmacopoeia (EP) Reference Standard
• CRS, European Pharmacopoeia (EP) Reference Standard
• Certified Reference Material
• British Pharmacopoeia (BP) Reference Standard
• BioReagent, suitable for fluorescence, ≥96.0% (HPLC)
• Batimastat primarily used in Inhibition.
• analytical standard
• AldrichCPR
• A potent inhibitor of HDACs and receptor tyrosine kinases
• A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV
• A cell-permeable, potent, reversible proteasome inhibitor (Ki = 4 nM).
• A cell-permeable piperazinyl-quinazolinone compound that exhibits oncogene-selective lethality.
• 99.99
• 99.9%
• ≥99.5%
• 99.5%
• ≥99.0% (NT)
• 99%+
• ≥99%, crystalline
• 99% purity
• 99% (HPLC Tested)
• 99% (High-quality, pharmaceutical grade)
• >99%
• 99%
• 98+
• 98.0-102.0%, solid
• >98.0%(T)(HPLC)
• >98.0%(T)
• >98.0%(HPLC)(N)
• >98.0%(HPLC)
• >98.0%(GC)
• ≥98% (TLC)
• ≥98% (HPLC), white to off-white, powder
• ≥98% (HPLC), solid
• >98% (HPLC), solid
• ≥98% (HPLC), powder
• ≥98% (HPLC), Mixture of E & Z isomers, solid
• >98% (HPLC)
• ≥98% (HPLC)
• >98%
• 98%
• 98 %
• 97-99%
• >97.0%(N)
• >97.0%(HPLC)
• ≥97% (HPLC), solid
• ≥97% (HPLC), powder
• ≥97% (HPLC)
• 97%
• >95.0%(T)(HPLC)
• >95.0%(HPLC)
• ≥95%, powder
• ≥95% (HPLC), powder
• >95% (HPLC)
• ≥95% (HPLC)
• >90.0%(HPLC)
• ≥90% (HPLC)
• 90 % Above
• 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material, Cerilliant?
• 1.0?mg/mL in methanol (as free base), ampule of 1?mL, certified reference material, Cerilliant?

Package

• 12μg
• 100μg
• 250μg
• 500μg
• 1mg
• 1.002mg
• 2mg
• 5mg
• 5.03mg
• 10mg
• 15mg
• 20MG
• 25mg
• 50mg
• 60mg
• 70mg
• 100mg
• 110mg
• 120mg
• 125MG
• 130mg
• 150mg
• 200mg
• 250mg
• 300mg
• 350mg
• 400mg
• 500mg
• 1gm
• 1000mg
• 1mL
• 1g
• 5gm
• 5g
• 5mL
• 10g
• 25g
• 100g
• 100ml
• 8009470521
• 25gm
• 8009472521
• 616451-5UNMG
• 50g
• 250ml
• 500mL
• 1SET
• 500g
• 1lt
• 1L
• 1kg
• 2500ml
• 2.5lt
• 2.5L
• 5kg
• 5lt
• 10L
• 10kg
• 25kg
• 25L
• 50L
• 50kg
• 2.5501e+00925 MG 50 MG 100 MG 250 MG EXTRA
• 100kg
• 0.5μmol
• 1MT
• 25Ltr
• 100μL
• 2.5501e+00925 MG 50 MG 100 MG 250 MG EXTRA
• 18%